Covid didn't help I'm sure.
Excuses bro...
November 10, 2020
Biotech innovator Stemson are scoping out research and development investments in the UK to develop a revolutionary cure for baldness in partnership with London-based Fortunis Capital as their lead investor in the country, it was announced today.
San Diego-based Stemson Therapeutics is developing technology to restore human hair growth with a novel approach using the patient’s own cells to generate new hair follicles.
Funding from impact investor Fortunis will support research and development of the product solution and position the UK as a leading contender to conduct human clinical trials,
Read More »
September 16, 2020
Stemson Therapeutics announced today a $7.5 million seed financing led by Allergan Aesthetics, an AbbVie Company, and impact investor Fortunis Capital to advance development of Stemson’s therapeutic solution to cure hair loss. Stemson aims to restore human hair growth with a novel approach using the patient’s own cells to generate new hair follicles.
See the press release
Read More »
September 14, 2020
Stemson Therapeutics announced approval in the United States of US patent No. 10716808, entitled “Methods and compositions to modulate hair growth” licensed exclusively from the Sanford Burnham Prebys Medical Discovery Institute. The patent covers a novel process developed by Stemson co-founder and Chief Scientific Officer, Alexey Terskikh, PhD, to differentiate Induced Pluripotent Stem Cells (iPSC) into dermal papilla cells, the cell type primarily responsible for controlling hair follicle generation and hair cycling. Issuance of this foundational patent provides stability surrounding the company’s efforts to develop its breakthrough iPSC-based solution for hair growth.
Read More »
September 8, 2020
Stemson Therapeutics is pleased to announce Meghan Samberg, PhD, joined our team as Vice President, R&D and Preclinical Development. Dr. Samberg will lead Stemson’s research and development efforts to prepare for human clinical trials of our hair growth cell therapy and will be responsible for helping drive regulatory and clinical strategy.
“Meghan brings extensive preclinical and clinical research experience and adds depth to the Stemson management team. Her expertise in tissue engineering strategies,